# Erasca

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/erasca

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.erasca.com
- Total disclosed funding: $201M
- Latest round: Series B (Aug 1, 2020)
- Investors on record: 12

## About

Based in California, US, and founded in 2018, Erasca, Inc. operates as a biotechnology company that focuses on developing drugs for the treatment of cancer. The company's name is a combination of the words erase cancer and was founded by Jonathan E. Lim. Erasca has raised a total of USD 300 million in funding over 4 rounds funded by 12 investors including Partner Fund Management and OrbiMed. In August 2020, Erasca raised USD 36 million in Series B funding. Erasca filed confidentially on the NASDAQ in May 2021 to become a public company under the ticker symbol ERAS. The company has 102 employees.

The company develops OPRA™, an AI-based platform that provides cancer biology insights. Erasca's drugs are developed through multiple discovery programs that are biological drivers of cancer, and the company is pursuing additional pipeline expansion opportunities through academic and biopharmaceutical collaborations, offering patients with new possible ways to treat and cure cancer. The company as of 2021 has five clinical-stage programs, including ERAS-007.

Erasca will begin its enrollment of a Phase 1b/2 trial in advanced solid tumors in May 2021. The company plans to begin three more Phase 1b/2a trials for ERAS-007 in other cancer indications by the first quarter of 2022.

## Funding rounds

- Series B, Aug 1, 2020, $12M — OrbiMed Advisors, Partner Fund Management
- Series B, Apr 27, 2020, $125M — ARCH Venture Partners, Colt Ventures, Invus [DUP], SG Growth Capital, City Hill Ventures, Cormorant Asset Management, LifeSci Partners, Terra Magnum Capital Partners
- Series A, Mar 5, 2019, $22M — ARCH Venture Partners, Andreessen Horowitz, LifeSci Partners, Reneo Capital
- Series A, Dec 17, 2018, $42M — City Hill Ventures, Cormorant Asset Management

## Investors

- City Hill Ventures (https://capitalatlas.ai/funds/city-hill-ventures) — Series A, Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A, Series B
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series A
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series A, Series B
- Reneo Capital — Series A
- Colt Ventures (https://capitalatlas.ai/funds/colt-ventures) — Series B
- Invus [DUP] — Series B
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series B
- Terra Magnum Capital Partners (https://capitalatlas.ai/funds/terra-magnum-capital-partners) — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Partner Fund Management — Series B